<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CE4FA0EC-37EA-4B26-BA91-4528C959C227"><gtr:id>CE4FA0EC-37EA-4B26-BA91-4528C959C227</gtr:id><gtr:name>Gustave-Roussy Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB"><gtr:id>6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB</gtr:id><gtr:name>University College London Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78"><gtr:id>C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78</gtr:id><gtr:name>Netherlands Cancer Institute</gtr:name><gtr:address><gtr:line1>Plesmanlaan 121</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2D017FB7-303D-48E6-AAFF-06303F046804"><gtr:id>2D017FB7-303D-48E6-AAFF-06303F046804</gtr:id><gtr:name>Royal Marsden NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC3E824E-993A-4DE4-89E3-F3DCA7ACC32C"><gtr:id>EC3E824E-993A-4DE4-89E3-F3DCA7ACC32C</gtr:id><gtr:name>St Bartholomew's Hospital</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:department>Cancer Research UK</gtr:department><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CE4FA0EC-37EA-4B26-BA91-4528C959C227"><gtr:id>CE4FA0EC-37EA-4B26-BA91-4528C959C227</gtr:id><gtr:name>Gustave-Roussy Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB"><gtr:id>6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB</gtr:id><gtr:name>University College London Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78"><gtr:id>C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78</gtr:id><gtr:name>Netherlands Cancer Institute</gtr:name><gtr:address><gtr:line1>Plesmanlaan 121</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2D017FB7-303D-48E6-AAFF-06303F046804"><gtr:id>2D017FB7-303D-48E6-AAFF-06303F046804</gtr:id><gtr:name>Royal Marsden NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC3E824E-993A-4DE4-89E3-F3DCA7ACC32C"><gtr:id>EC3E824E-993A-4DE4-89E3-F3DCA7ACC32C</gtr:id><gtr:name>St Bartholomew's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/70E0CFAB-14BC-4FDE-9CF7-67F47EFD530E"><gtr:id>70E0CFAB-14BC-4FDE-9CF7-67F47EFD530E</gtr:id><gtr:firstName>Marco</gtr:firstName><gtr:surname>Gerlinger</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0902275"><gtr:id>69E646ED-0BF3-4CFD-97A5-4B39091210B9</gtr:id><gtr:title>Functional genomic identification of predictive biomarkers of everolimus sensitivity and of new molecular targets in ren</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0902275</gtr:grantReference><gtr:abstractText>Everolimus is an effective new drug for the treatment of kidney cancer, however not all patients respond to everolimus and even those who respond develop resistance after 6-9 months of treatment. We will use a technique called ?functional genomics? to de-activate each of the 21.000 human genes individually in kidney cancer cells grown in the laboratory, to identify genes that can lead to everolimus resistance. Resistance genes will be further studies to understand how resistance develops and how it can be prevented or treated. We will also analyse kidney cancer samples from patients treated with everolimus to determine whether the identified resistance genes are commonly altered in resistant cancers. This should lead to the development of a test that can determine whether a patient with kidney cancer is likely to respond to everolimus before treatment is actually started. Such a test would spare patients with resistant disease the side effects of the treatment and improve their quality of life. Everolimus is not approved for the use in the NHS because of the high costs. A test that allows targeting the drug to patients with sensitive disease would reduce overall costs and hopefully make it available to NHS patients.</gtr:abstractText><gtr:technicalSummary>Background:

The mTOR (mammalian Target Of Rapamycin) inhibitor everolimus is active in renal cell carcinoma (RCC) but intrinsic and acquired drug resistance limits efficacy. Everolimus has direct cytostatic effects on RCC cells and anti-angiogenic activity through the suppression of hypoxia inducible factor 1 (HIF1 ) and its target VEGF in von-Hippel-Lindau (VHL)-gene deficient RCCs, and by inhibiting mTOR in endothelial cells. Mechanisms of everolimus resistance are poorly understood and there are no reliable predictive biomarkers of response.

Aims: 

Whole genome siRNA screens will be applied to RCC cell lines to identify genes that mediate resistance to the cytostatic effect of everolimus, the hypoxic environment generated by its anti-angiogenic activity, and to the suppression of the HIF1 -VEGF pathway by mTOR inhibition. These results and their integration with transcriptomic and genomic profiles of pre- and post-treatment tumour samples from a clinical trial of everolimus in patients with RCC will identify:

1. Clinically relevant resistance mechanisms 
2. Predictors of everolimus sensitivity and resistance
3. Therapeutic targets leading to synthetic lethality in VHL deficient RCC cell lines

Design and methodology:

A siRNA screen has already been performed in a VHL deficient RCC cell line and identified novel mediators of everolimus resistance and sensitivity. Further immunostaining of this screen for carbonic anhydrase IX as a marker for HIF1 activity will identify genes that contribute to in vivo resistance by rescuing HIF1 activity and -target gene expression in the presence of everolimus. A second siRNA screen will be performed to reveal how RCC cells can develop resistance to hypoxic conditions. Resistance mechanisms will be further characterized in vitro and by systems biology approaches. Screening results will be compared with mRNA expression, copy number variation and whole genome exon capture sequencing datasets obtained from pre- and post- treatment RCC tumour samples to identify which genes are relevant to resistance in patients. Candidate predictive biomarkers will be assessed in a validation cohort. Genes causing synthetic lethality in the VHL-null background when repressed will be identified in isogenic VHL-wt and VHL-null cell lines.

Scientific and clinical opportunities:
This approach should lead to the identification of a predictive biomarker of everolimus response in RCC. It should simultaneously define molecular mechanisms of resistance and potential targets to facilitate the development of new therapeutic strategies. These strategies could reduce the health economic burden associated with therapeutic resistance and improve outcomes in RCC by targeting treatment to patients with molecularly pre-defined drug sensitive disease.</gtr:technicalSummary><gtr:fund><gtr:end>2014-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>746916</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Marsden NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>PREDICT Consortium</gtr:description><gtr:id>10BE0D4A-BADF-4C16-A7AD-2AA7997F9C17</gtr:id><gtr:impact>Detailed description of intratumour heterogeneity in kidney cancer 
The work had profound impact on precision cancer medicine as our description of intratumour heteroegenity and cancer evolution has wide implications on biomarker development and drug development. 
The work led to large clinical trials including the CRUK TRACERx trial (CI: Swanton)</gtr:impact><gtr:outcomeId>habqGKBwz7e-1</gtr:outcomeId><gtr:partnerContribution>Provision of clinical samples and expertiseProvision of clinical samples and expertiseProvision of clinical samples and expertiseProvision of clinical samples and expertise</gtr:partnerContribution><gtr:piContribution>Our lab performs molecular analysis of tumour specimens and generates correlating functional in vitro data to identify mechanisms of drug resistance</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Bartholomew's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Medical Oncology Department St Barts</gtr:department><gtr:description>PREDICT Consortium</gtr:description><gtr:id>228F645A-0B0E-40E2-A2B7-73D73207D7FF</gtr:id><gtr:impact>Detailed description of intratumour heterogeneity in kidney cancer 
The work had profound impact on precision cancer medicine as our description of intratumour heteroegenity and cancer evolution has wide implications on biomarker development and drug development. 
The work led to large clinical trials including the CRUK TRACERx trial (CI: Swanton)</gtr:impact><gtr:outcomeId>habqGKBwz7e-3</gtr:outcomeId><gtr:partnerContribution>Provision of clinical samples and expertiseProvision of clinical samples and expertiseProvision of clinical samples and expertiseProvision of clinical samples and expertise</gtr:partnerContribution><gtr:piContribution>Our lab performs molecular analysis of tumour specimens and generates correlating functional in vitro data to identify mechanisms of drug resistance</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Netherlands Cancer Institute (NKI)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>PREDICT Consortium</gtr:description><gtr:id>6A2E17A7-52FB-48DB-8EF1-A3D848F55A52</gtr:id><gtr:impact>Detailed description of intratumour heterogeneity in kidney cancer 
The work had profound impact on precision cancer medicine as our description of intratumour heteroegenity and cancer evolution has wide implications on biomarker development and drug development. 
The work led to large clinical trials including the CRUK TRACERx trial (CI: Swanton)</gtr:impact><gtr:outcomeId>habqGKBwz7e-4</gtr:outcomeId><gtr:partnerContribution>Provision of clinical samples and expertiseProvision of clinical samples and expertiseProvision of clinical samples and expertiseProvision of clinical samples and expertise</gtr:partnerContribution><gtr:piContribution>Our lab performs molecular analysis of tumour specimens and generates correlating functional in vitro data to identify mechanisms of drug resistance</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Barts Cancer Institute</gtr:department><gtr:description>Circulating Tumour DNA analysis in Prostate Cancer</gtr:description><gtr:id>863C1D19-0561-4ED2-8D77-6EB88C1C97D2</gtr:id><gtr:impact>This project has started this year and first results are expected next year.</gtr:impact><gtr:outcomeId>Gbc6Meiig9B-1</gtr:outcomeId><gtr:partnerContribution>All partners are clinicians who will contribute to sample and data collection and pathology reporting.</gtr:partnerContribution><gtr:piContribution>I designed the genetic tests which will be applied to patients specimens to trace genetic changes in prostate cancer in patients undergoing treatment. I also provided feasibility data from my renal cancer work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gustave-Roussy Institute</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Gustave-Roussy Institute of Oncology</gtr:department><gtr:description>PREDICT Consortium</gtr:description><gtr:id>19AD9A32-387F-45B4-BDB1-8841CE283E20</gtr:id><gtr:impact>Detailed description of intratumour heterogeneity in kidney cancer 
The work had profound impact on precision cancer medicine as our description of intratumour heteroegenity and cancer evolution has wide implications on biomarker development and drug development. 
The work led to large clinical trials including the CRUK TRACERx trial (CI: Swanton)</gtr:impact><gtr:outcomeId>habqGKBwz7e-2</gtr:outcomeId><gtr:partnerContribution>Provision of clinical samples and expertiseProvision of clinical samples and expertiseProvision of clinical samples and expertiseProvision of clinical samples and expertise</gtr:partnerContribution><gtr:piContribution>Our lab performs molecular analysis of tumour specimens and generates correlating functional in vitro data to identify mechanisms of drug resistance</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Urology</gtr:department><gtr:description>Intra-Tumour Heterogeneity in Prostate Cancer</gtr:description><gtr:id>5FFB4C11-7723-4224-9A7E-A474688A6E40</gtr:id><gtr:impact>Publication submitted</gtr:impact><gtr:outcomeId>H4hDDBjUZcW-1</gtr:outcomeId><gtr:partnerContribution>The urology team at UCL is responsible for samples collection and contributed significantly to the clinical questions we are trying to answer.</gtr:partnerContribution><gtr:piContribution>We have designed the genetic analyses necessary to perform this research project and will do the sequencing and data analysis similar to our recent work in renal cancer.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Lab Tours for CRUK fundraisers and donors</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>A92B60BF-5F85-4944-ACA7-99BD30231AAF</gtr:id><gtr:impact>Groups of 2-10 people visit our lab approximately every other month for a guided lab tour.

High interest in our work</gtr:impact><gtr:outcomeId>DkHo8uPwauZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prostate Cancer UK Starter Grant</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:fundingRef>PA12-15</gtr:fundingRef><gtr:id>34FFB8B8-0359-41DA-8662-DB5435539010</gtr:id><gtr:outcomeId>Sso6Rg7Nk1a</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK BIDD Genomics Initiatics</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>05EA28D3-D815-4AC2-A2E5-32EAC72DA413</gtr:id><gtr:outcomeId>Mfok8H2gMHV0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>The first multi-region exome sequencing dataset from 10 clear cell renal cell carcinomas was generated through my MRC award and deposited in the EPG public archive. This dataset has been used by multiple researchers subsequently to investigate the impact of intratumour heterogeneity on disease biology and precision cancer medidine</gtr:description><gtr:id>1632B0D6-66ED-4382-BF92-A80DCA9E6027</gtr:id><gtr:impact>Our publication in Nature Genetics 2014 and European Urology in 2014. 

In addition, the dataset has been used by multiple other groups and publications have arisen from this. It is also hosted on the cBIO cancer genomics portal at the Memorial Sloan Kettering Cancer Centre</gtr:impact><gtr:outcomeId>56e145a75ed985.53402574</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Kidney cancer multi region exome sequencing dataset</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>https://www.ebi.ac.uk/ega/studies/EGAS00001000667</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>26FFD78B-21DC-4D30-9BDD-7EE37689B018</gtr:id><gtr:title>Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e63997bc466ab652e033701241210d4"><gtr:id>4e63997bc466ab652e033701241210d4</gtr:id><gtr:otherNames>Gerlinger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>54f6d3d841d055.07969068</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1659579A-8B74-4AD6-A4DB-DAC5A9894504</gtr:id><gtr:title>How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e63997bc466ab652e033701241210d4"><gtr:id>4e63997bc466ab652e033701241210d4</gtr:id><gtr:otherNames>Gerlinger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_12930_20_20877357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CB6BA51-BCD0-4462-A55D-1E7BFDE71AF4</gtr:id><gtr:title>Intratumor heterogeneity: seeing the wood for the trees.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a47a480c4dfc6358b9a2a6fcc3232896"><gtr:id>a47a480c4dfc6358b9a2a6fcc3232896</gtr:id><gtr:otherNames>Yap TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>pm_12930_20_22461637</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A18EA182-264A-4FE1-A60A-D12369CF8BA7</gtr:id><gtr:title>SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/965f66374803d1235c359b4723d40be4"><gtr:id>965f66374803d1235c359b4723d40be4</gtr:id><gtr:otherNames>Kanu N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>585d58fd332c98.48914022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>892B9500-0EA0-4C1D-BC4F-31C7CA96DF76</gtr:id><gtr:title>Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e63997bc466ab652e033701241210d4"><gtr:id>4e63997bc466ab652e033701241210d4</gtr:id><gtr:otherNames>Gerlinger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_12930_20_22362593</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BB9A88C-472C-4574-953E-0835F2358342</gtr:id><gtr:title>Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19ccad6cd2a8ba4894acba2cc6a199eb"><gtr:id>19ccad6cd2a8ba4894acba2cc6a199eb</gtr:id><gtr:otherNames>Juul N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>pm_12930_20_20189874</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C31C492-B92D-4531-B891-BBF3A9FC35F6</gtr:id><gtr:title>Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb8c44c50844da0abcb890cbc48974e3"><gtr:id>fb8c44c50844da0abcb890cbc48974e3</gtr:id><gtr:otherNames>Gulati S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>54f6d388e19ee8.92019516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F3C9947-BC30-4057-AD32-90CDEAA09C7A</gtr:id><gtr:title>The promise of circulating tumor cell analysis in cancer management.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac458ba764e6d39fc2c88ac7aeef879f"><gtr:id>ac458ba764e6d39fc2c88ac7aeef879f</gtr:id><gtr:otherNames>Mateo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>54f6d38954a742.41178143</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDBE7A34-F986-4CA8-B8E4-7D711273AC95</gtr:id><gtr:title>Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ddd6af6f82dfd5ca496430fd1a81007"><gtr:id>7ddd6af6f82dfd5ca496430fd1a81007</gtr:id><gtr:otherNames>Crusz SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>58c692a92edd21.92777258</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>729D5DD4-635F-4B38-A7C1-9F7FFEED9D6A</gtr:id><gtr:title>Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e63997bc466ab652e033701241210d4"><gtr:id>4e63997bc466ab652e033701241210d4</gtr:id><gtr:otherNames>Gerlinger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_12930_20_22397650</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48DD97B6-F5A1-43BC-BF10-58FC9014762C</gtr:id><gtr:title>Cancer: evolution within a lifetime.</gtr:title><gtr:parentPublicationTitle>Annual review of genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e63997bc466ab652e033701241210d4"><gtr:id>4e63997bc466ab652e033701241210d4</gtr:id><gtr:otherNames>Gerlinger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0066-4197</gtr:issn><gtr:outcomeId>54f6d3898042e6.95246570</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C5D7C76-98F3-429D-B8D4-49A69E9F3247</gtr:id><gtr:title>Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e63997bc466ab652e033701241210d4"><gtr:id>4e63997bc466ab652e033701241210d4</gtr:id><gtr:otherNames>Gerlinger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_12930_20_24487277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD7A69CB-F7A0-4A15-91F0-B43346D98892</gtr:id><gtr:title>Prognostic and predictive markers in metastatic renal cell carcinoma.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47415f192f4ccc56f0233ea0c0905afe"><gtr:id>47415f192f4ccc56f0233ea0c0905afe</gtr:id><gtr:otherNames>Khattak MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>pm_12930_20_23295806</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81B8049D-0EB1-4339-B277-109B514B7A94</gtr:id><gtr:title>Computational optimisation of targeted DNA sequencing for cancer detection.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f6e2e87ecaf71ccc13c4b255445d8cb"><gtr:id>4f6e2e87ecaf71ccc13c4b255445d8cb</gtr:id><gtr:otherNames>Martinez P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>pm_12930_20_24296834</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79E972C0-B867-4A2F-B266-1D4369126F97</gtr:id><gtr:title>Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eca47545771457775484443c13a39857"><gtr:id>eca47545771457775484443c13a39857</gtr:id><gtr:otherNames>Favero F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>54f6d38a76a284.71296529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FC3ABC3-8BE1-4DA6-989D-6D376A492ABD</gtr:id><gtr:title>Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5f89bc266f10341c365606e24326bd0"><gtr:id>e5f89bc266f10341c365606e24326bd0</gtr:id><gtr:otherNames>Swanton C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn><gtr:outcomeId>pm_12930_20_20701793</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4854A406-C6D7-4252-82D9-559D2F257361</gtr:id><gtr:title>Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee27c9007a94a32a996f3bcf9092c9ae"><gtr:id>ee27c9007a94a32a996f3bcf9092c9ae</gtr:id><gtr:otherNames>Fisher R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>54f6d38925e415.34242342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD04C6E8-F3DA-4510-9199-CE011F07E17C</gtr:id><gtr:title>Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89595353ebee348e44bedd27c10e267b"><gtr:id>89595353ebee348e44bedd27c10e267b</gtr:id><gtr:otherNames>Tan DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>pm_12930_20_20413300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FC53C73-043B-4EC6-8FD4-1B1536797146</gtr:id><gtr:title>Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7468e5ee2202bec764eff3c295f73d2f"><gtr:id>7468e5ee2202bec764eff3c295f73d2f</gtr:id><gtr:otherNames>de Bruin EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>54f6d389acaf87.74304551</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FB0C25B-9F84-4FC2-91A9-3A6C063E68E4</gtr:id><gtr:title>The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/efd25d53071e799287d076c94d32fd4e"><gtr:id>efd25d53071e799287d076c94d32fd4e</gtr:id><gtr:otherNames>Sharpe K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_12930_20_24130073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>785C09B8-7F18-4FF2-989A-C991407077BF</gtr:id><gtr:title>Parallel evolution of tumour subclones mimics diversity between tumours.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f6e2e87ecaf71ccc13c4b255445d8cb"><gtr:id>4f6e2e87ecaf71ccc13c4b255445d8cb</gtr:id><gtr:otherNames>Martinez P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_12930_20_23716380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>081D4AC3-9BCF-4602-8595-C72942248CB1</gtr:id><gtr:title>ESMO Handbook of Translational Research</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f813ff301eb92f5a4aa07abc3da82cec"><gtr:id>f813ff301eb92f5a4aa07abc3da82cec</gtr:id><gtr:otherNames>Ashenden M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:isbn>9788890635977</gtr:isbn><gtr:outcomeId>56ddac368935f9.69884070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A276F670-9C01-468D-8BF3-14299FBE9E32</gtr:id><gtr:title>Acquired resistance to crizotinib from a mutation in CD74-ROS1.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e63997bc466ab652e033701241210d4"><gtr:id>4e63997bc466ab652e033701241210d4</gtr:id><gtr:otherNames>Gerlinger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_12930_20_24047073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DCD8179-1ADC-48BE-A795-C2CD841BB407</gtr:id><gtr:title>Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e63997bc466ab652e033701241210d4"><gtr:id>4e63997bc466ab652e033701241210d4</gtr:id><gtr:otherNames>Gerlinger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_12930_20_24122851</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72AD35A5-F6C4-4188-8BFC-781C0555D715</gtr:id><gtr:title>Translating Seminoma Genomic Landscapes into Clinical Practice.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e63997bc466ab652e033701241210d4"><gtr:id>4e63997bc466ab652e033701241210d4</gtr:id><gtr:otherNames>Gerlinger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>54f6d38a1a3ec9.54255560</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902275</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>